Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-06 10:52 am Sale | 2025-02-28 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 0 0.000% | -5,686,631 (Position Closed) | Filing History |
| 2025-02-13 4:02 pm Sale | 2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 1,611,787 1.540% | -3,625,497 (-69.22%) | Filing History |
| 2025-02-11 12:16 pm Purchase | 2024-12-31 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 5,686,631 5.400% | 2,917,940 (+105.39%) | Filing History |
| 2025-02-06 6:19 pm Purchase | 2025-01-30 | 13G | Revance Therapeutics, Inc. RVNC | GLAZER CAPITAL LLC | 7,210,121 6.870% | 7,210,121 (New Position) | Filing History |
| 2025-01-30 09:01 am Unchanged | 2025-01-30 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing History |
| 2025-01-10 4:52 pm Purchase | 2025-01-02 | 13G | Revance Therapeutics, Inc. RVNC | Beryl Capital Management LLC | 6,359,570 6.100% | 4,717,122 (+287.20%) | Filing History |
| 2025-01-06 09:00 am Unchanged | 2025-01-06 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing History |
| 2024-12-19 09:00 am Unchanged | 2024-12-19 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing History |
| 2024-10-31 1:20 pm Sale | 2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC | FRANKLIN RESOURCES INC BEN | 4,784,658 4.600% | -1,323,619 (-21.67%) | Filing History |
| 2024-10-23 7:17 pm Sale | 2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 0 0.000% | -5,825,881 (Position Closed) | Filing History |
| 2024-10-07 10:08 am Sale | 2024-10-07 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 0 0.000% | -6,948,769 (Position Closed) | Filing History |
| 2024-09-16 5:01 pm Purchase | 2024-09-05 | 13G | Revance Therapeutics, Inc. RVNC | Beryl Capital Management LLC | 1,642,448 1.600% | 1,642,448 (New Position) | Filing History |
| 2024-09-09 10:40 am Sale | 2024-09-09 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 6,948,769 6.600% | -4,990,307 (-41.80%) | Filing History |
| 2024-04-09 1:17 pm Sale | 2024-03-29 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 2,768,691 2.600% | -1,986,080 (-41.77%) | Filing History |
| 2024-02-14 4:55 pm Sale | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 5,237,284 5.960% | -46,325 (-0.88%) | Filing History |
| 2024-02-14 3:45 pm Sale | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Antara Capital LP | 0 0.000% | -5,239,600 (Position Closed) | Filing History |
| 2024-02-13 5:13 pm Purchase | 2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC | The Vanguard Group | 5,069,625 5.770% | 573,309 (+12.75%) | Filing History |
| 2024-02-13 09:39 am Sale | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Polar Capital Holdings Plc | 3,169,239 3.600% | -1,679,394 (-34.64%) | Filing History |
| 2024-02-09 6:21 pm Purchase | 2024-02-07 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 11,939,076 13.600% | 2,458,920 (+25.94%) | Filing History |
| 2024-02-09 10:05 am Purchase | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | GIC Private Ltd | 5,825,881 6.630% | 332,916 (+6.06%) | Filing History |